Mon, Jan 26, 2015, 5:58 AM EST - U.S. Markets open in 3 hrs 32 mins

Recent

% | $
Quotes you view appear here for quick access.

Cytori Therapeutics, Inc. Message Board

rothco619 22 posts  |  Last Activity: Jan 23, 2015 12:18 PM Member since: Aug 29, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Chris gets paid again, and again, and

    by ceingisbeleeving Oct 28, 2014 5:20 PM
    rothco619 rothco619 Oct 29, 2014 10:28 AM Flag

    You can't be serious if you think that CC is done draining every nickle he can from Cytori. Did not think it possible that things could get worse with Hedrik but it didn't take long to prove that theory wrong. With Rickey as COB they have they guy in place that will be sure these crooks get every nickle they can. If you expect anything to change until every one of these frauds are tossed out on there keysters then your a bigger fool then all of us have been and unfortunately that would take some doing.

  • rothco619 rothco619 Nov 5, 2014 12:54 PM Flag

    your are not very well informed about CYTX at all. Maxim underwrote the secondary and owns all the shares clients want at .50

  • Reply to

    A lot of new activity and contracts.

    by agamemnus_0 Nov 6, 2014 4:17 PM
    rothco619 rothco619 Nov 6, 2014 4:19 PM Flag

    You are absolutely completely clueless when it comes to this company. You really need to go back and do some DD, as you make a fool of yourself each time you post unless of course that is your intention.

  • Don't let scammers on this MB fool you. No reverse split. Price will be above $1 . Japan legislation interpreted and will provide immediate benefit well in time of delisting limits. Info will follow shortly. This MB is now only for shorts and day traders.

    Legislation in Japan Passes
    Summary
    We have reviewed a press release from Mesoblast that gave us insight into
    new Japanese legislation (PMD Act). We paraphrase the data from Mesoblast,
    emphasizing the data is from Mesoblast and not based on our own independent
    second source:
    • Conditional product approvals will be based on existing Phase II trial results
    demonstrating probable efficacy and safety with bridging studies in Japanese
    patients.
    • Conditional approvals will allow sales of each product candidate for up to 7
    years.
    • Conditionally approved products will be covered by health insurance.
    • Conditional approvals will cover allogeneic cell therapy product candidates
    manufactured under GMP outside of Japan; and full approval is expected to
    require further confirmation of safety and efficacy in a larger population.
    Conclusion: We believe the legislation (as stated from Mesoblast) represents
    a best-case scenario for companies like Mesoblast, Pluristem, and Athersys
    (allogeneic players), as well as autologous companies like Cytori and others

  • rothco619 rothco619 Dec 4, 2014 3:11 PM Flag

    Presentation was a complete waste of time. Submitted 5 questions or more but they were tough ones so of course marc would not touch them. Transparency to shareholders what a crock ! Same old company, same old BS,same old pie in the sky promises. Was hoping for more that maybe there would be a chance to recoup some of my losses but wouldn't count on it 10 times my wildest dreams my A $ $

  • Reply to

    Best Case Scenario for Cytori

    by wall_street_titan Dec 5, 2014 11:50 AM
    rothco619 rothco619 Dec 5, 2014 2:34 PM Flag

    When pigs fly. You have been wrong on everything you have ever written on Cytx,just as eveything we have ever been told by management or board members has been a lie. 10x's my wildest dreams my A $ $

  • Reply to

    Best Case Scenario for Cytori

    by wall_street_titan Dec 5, 2014 11:50 AM
    rothco619 rothco619 Dec 6, 2014 6:04 PM Flag

    All mangement has been around for years and has gone down every wrong road, pi$$ed away money,failed to get a partnership or monetize anything. No sense rehashing what we all know. point is , Marc Hedrcik is part of a failed regime. His fingerprints are all over the failures and he does not even talk a good game. Technology is good, we have probably lost any competitive advantages we had . It's not like it's been just 2 years or 5 yesr or 8 years or 10 years or 15 years and so on. This group that couldn't shoot straight has been and is doomed for failure. Someone will montize this tech. in some way shape or form.

  • Reply to

    Best Case Scenario for Cytori

    by wall_street_titan Dec 5, 2014 11:50 AM
    rothco619 rothco619 Dec 8, 2014 11:07 AM Flag

    I seriously doubt he is #$%$ off as he has most luikely shorted all the way down and so his actual out of pocket is quite minimal compared to the $3 a share he shelled out. He could do that with his class of shares. Probably why they did not go to the credit line and decised to kill the share price so that KT can eventually get as many cheap shares as he wants at thye expense of course of all us suckers who have held , lost big bucks and are down 90% on our investments. Very sad that if today i took the money I've invested in this pig i'd have well over 500,000 shares. I'm chocking help!!

  • Reply to

    And there's your news flow....

    by cognitive_basher Dec 10, 2014 8:07 AM
    rothco619 rothco619 Dec 10, 2014 10:30 AM Flag

    good story., but where is the money coming from to fund the trial ? More dilution, another imaginary partnership, or Marc's fairy god mother ?

  • rothco619 by rothco619 Dec 10, 2014 10:33 AM Flag

    Put a $5 in front of the .50 and I'm even on huge investment that is killing me. Oh how the mighty have fallen when .50 gets you excited great job to Marc and the Cytori team you have all been inspirational leaders,not

  • rothco619 rothco619 Dec 11, 2014 11:26 AM Flag

    Won't fly until pigs do. Looks like new crop of suckers/investors have grandios expectations. All must realize that technology is not in question it is the bozo's driving the bus and that has not changed. the definition of insanity is doing the same thing ovwer and over and expecting a different result. The CYTX bus has been driven right into a ditch on the side of a snowy vermont road. A seasons worth of snow has covered the bus and now that snow needs to melt and the bus needs to thaw. All the while the competiton has caught up, money has been #$%$ e d away the market cap is an embarassment. The good news for new investors is that if this pig does ever take off they will be far more profitable the us who have lost 90% of our money and all that Marc hedrick can offer are his insincere apologies, and empty promises of transparency and that delisting will not happen because the share price will be higher due to execution. Old song that has been sung so many times you don't want to listen.

  • rothco619 rothco619 Jan 12, 2015 10:32 AM Flag

    Cytori goes nowhere with this inept management team in place. You talk of new management yet there is no new management perhaps addition by subtraction. The only new member of the team is the CFO who orchestrated the sell out of loyal shareholders and gave the company away. Now the same group will dilute shares even further by doubling the amount of shares issued. Guess if you never heard of Cytori before and wanted to take a flier on a penny stock, perhaps there is justification. Do not ever fall into the trap believing that this Board or management team gives a rats A$$ about creating shareholder value or improving communication or relations with shareholders. There is not a singe long that owns Cytori for 2 + years that is not in the red on this stock. Anyone who claims that they are is an outright liar. If your short your a happy camper, if you believed in the tech and believed in the bs that Cytori has been feeding everyone for some 15 years since it's inception in the form of one company or another, you have been extremely disappointed and have nothing to show for it except gray hairs and losses. Sorry street but both you and DOV, who are honorable people , intelligent , and well intentioned have guided many to financial ruin. Not your fault as all must do there own DD and are responsible for buying this POS , however, until Cytori actually come through on a single promise and shows that they are on the road to financial stability,you owe it to any of your readers to tell the whole story. The YMB has been over run with day traders and shorts who are only interested in pumping and dumping. We even have the reincarnation of old shorts operating under new ID's and posting worthless messages daily.

  • rothco619 by rothco619 Jan 12, 2015 1:53 PM Flag

    Cytori Therapeutics Inc (CYTX - NASDAQ - $0.51 )

    Buy
    Target Price: $6.00
    Cytori Gets Final IDE Approval - Let the Trial Begin!
    Summary:

    •Cytori announced that it has received final approval of the Investigational Device Exemption (IDE) to begin a pivotal trial for impaired hand function in scleroderma. This follows December's announcement of a conditional approval, and is good news that allows the 'STAR' trial to begin enrolling patients as expected. If the trials is successful, it should be enough for FDA approval.
    •There are no changes to the plans to enroll 80 patient in up to 12 centers in the US. The 'STAR' trial is a phase II/III pivotal trial, based on phase I data (proof of concept) from an investigator-initiated trial in France that was published late this summer. (Paper Link)
    •Cytori will hold two meetings in San Francisco this week. An information session with its CEO is scheduled for Monday, January 12 at 3:30 PST at the Biotech Showcase in San Francisco. An information session with the STAR trial's Principal Investigator is planned for Wednesday, January 14 at the Prescott Hotel, 545 Post Street, Room 736 from 1:30 to 4:30 PST.
    •We believe that Cytori now has an accelerated pathway to ADRC approval for Scleroderma and combined with the expected release of a next generation Celution System in early 2015, is poised for a valuation inflection.

    Details:

    Phase I Study results. Twelve Scleroderma patients received autologous ADRCs by subcutaneous injection into each finger. Primary endpoints were safety and tolerability at 2 and 4 months, which were met and no adverse events reported. Secondary endpoints showed sustained, statistically significant improvements for hand and diabililty pain, Raynauds’s phenomenon (discoloration of extremities and pain due to lost blood flow), and quality of life at 2 and 6 months.

    Key Data Points. Hand disability was reduced, as measured by a decrease from baseline in the Cochin Hand Function Scale at both two

  • Reply to

    For What It's worth

    by rothco619 Jan 12, 2015 1:53 PM
    rothco619 rothco619 Jan 12, 2015 1:56 PM Flag

    Key Data Points. Hand disability was reduced, as measured by a decrease from
    baseline in the Cochin Hand Function Scale at both two months (47.4%) and six
    months (56.0%); Hand pain was diminished, as measured in visual analog score
    at both two months (37.8%) and six months (41.7%); Raynaud’s phenomenon was
    reduced, as measured by a decrease from baseline in the Raynaud’s Condition
    Score at both two months (53.7%) and six months (67.5%); and Overall quality of life
    was improved, as measured by a decrease from baseline in the Scleroderma Health
    Assessment Questionnaire scores at both two months (45.2%) and six months
    (42.4%).
    What is Scleroderma? Scleroderma is an autoimmune disorder that causes skin
    fibrosis and destructive changes in blood vessels due. Scleroderma is a systemic
    disease that affects the major organs but most commonly causes changes in the skin
    and hands, often resulting in disability, diminished mobility and pain. Care is largely
    palliative and is based on treatment standards for Raynauds’s phenomenon. There
    are 75,000 scleroderma patients in the US alone and most have hand manifestations
    of the disease. This represents an opportunity for Cytori to advance the ADRC
    franchise. The patient population is not large but the cost of care is high, likely
    resulting in significant market penetration quickly.
    Valuation. We assume Cytori will be successful in Scleroderma and multiple
    other indications utilizing ADRCs (thermal burns, stress urinary incontinence, and
    osteoarthritis. We apply a 25% risk cut to our therapeutic model and a 30% discount
    to financial models for FCFF, discounted EPS, and SOP to arrive at a $6.00 price
    target.

  • Reply to

    For What It's worth

    by rothco619 Jan 12, 2015 1:53 PM
    rothco619 rothco619 Jan 12, 2015 3:18 PM Flag

    That is a very good point, but according to Dov when he had a conversation with the management team Hendrik was saying it had been delayed due to financing. This made no sense to me as I pointed out on the Fas board as BARDA funding is paying for this development. It makes no sense that getting this next generation machine to market should not be #1 priority as success of the company depends on it. There are old cellution machines that are out on loan that can be used for trials but surely nobody is going to buy them for the six figure price tag on them. This is the problem with Cytori they lay out a timeline as Hendrik did during his virtual call and then weeks later renigs on the promise.

  • Reply to

    Reverse split explained by Robshem2006 !!!

    by belgiumineurope Jan 15, 2015 3:29 AM
    rothco619 rothco619 Jan 15, 2015 10:32 AM Flag

    Hedrik has stated in no uncertain terms that he does not feel a delisiting is in the cards and that the stock will be above a dollar without reverse split. This will be a true test of his credibility and if it does not come to fruition then the board should ask him to step down. This is not as bold a prediciton as made by our over zealous x COB, LLyod dean who promised us 10 X's our wildeset dreams and encourging shareholders to double down.while only delivering our worst nightmare. For me the perception is that Cytori is foundering and completely lacking direction. It becomes more evident
    to me that as structured this team can't make it happen. Enthusiasm breeds enthusiam and I'm just not jumping up and down over thwe prospects and I should be at under .50,but been Calhouned for the last time . Wake up Cytori and give shareholders something to be proud of.

  • Reply to

    Hedrick Better Start Producing Quickly

    by rodney.strongg Jan 15, 2015 10:27 AM
    rothco619 rothco619 Jan 15, 2015 12:41 PM Flag

    Hedrik has stated in no uncertain terms that he does not feel a delisiting is in the cards and that the stock will be above a dollar without reverse split. This will be a true test of his credibility and if it does not come to fruition then the board should ask him to step down. This is not as bold a prediciton as made by our over zealous x COB, LLyod dean who promised us 10 X's our wildeset dreams and encourging shareholders to double down.while only delivering our worst nightmare. For me the perception is that Cytori is foundering and completely lacking direction. It becomes more evident
    to me that as structured this team can't make it happen. Enthusiasm breeds enthusiam and I'm just not jumping up and down over thwe prospects and I should be at under .50,but been Calhouned for the last time . Wake up Cytori and give shareholders something to be proud of.

  • rothco619 rothco619 Jan 20, 2015 10:03 AM Flag

    Yes, I see the positive affects the Roth and maxim releases have had today. It should be illegal for companies underwriting a secondary to write this BS for the sole purpose of pumping a stock before more dilution. Yet they continue to get away with it, looks #$%$ investors have caught on and nobody buying it. Only took a house and building to fall on us to get it.

  • rothco619 rothco619 Jan 20, 2015 10:05 AM Flag

    Oh yes a big sqeeze on a .49 stock and cytori's track record. I am sure the shorts are shaking in there boots.

CYTX
0.4789-0.0009(-0.19%)Jan 23 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.